Abstract:We read with interest the article by Riener et al.1 reporting the potential usefulness of Golgi Phosphoprotein 2 (GOLPH2) as a new serum biomarker for diagnosing hepatocellular carcinoma (HCC). We would like to draw attention to similar studies on the use of serum GOLPH2 in the differentiation of HCC patients from controls with no liver disease and patients with cirrhosis. GOLPH2 was originally described as a resident Golgi type II transmembrane protein expressed primarily in epithelial cells of many human tissues.2 In the normal human liver, GOLPH2 expression was found in biliary epithelial cells, but it was barely detectable in hepatocytes. However, expression of GOLPH2 was found to be strongly up-regulated in hepatocytes from patients with viral and nonviral liver diseases.3 A recent study showed that GOLPH2 was detected in human serum, and it was found to be elevated in the serum and tissue in the woodchuck model of HCC in comparison with the nonneoplastic liver.4 Thus, GOLPH2 may be a potential marker for the early detection of HCC. We tested the serum GOLPH2 levels in patients with HCC (50), patients with cirrhosis (50), and controls with no liver disease (50). Our results showed that GOLPH2 was detected in the sera of all patients, but the levels were higher in patients with HCC and cirrhosis in comparison with controls with no liver disease. Median serum GOLPH2 levels were 1.35 relative units (range, 0.52–12.99) in controls with no liver disease, 4.39 relative units (range, 0.52–26.78) in patients with cirrhosis, and 14.37 relative units (range, 1–57) in those with HCC (P < 0.0001 for HCC versus patients with cirrhosis and controls with no liver disease). Median serum alpha-fetoprotein (AFP) levels were 2.46 ng/mL (range, 1.15–7.68) in controls with no liver disease, 6.11 ng/mL (range, 0.28–625) in patients with cirrhosis, and 16.2 ng/mL (range, 0.89–352,000) in HCC patients (P < 0.0001 for HCC patients versus controls with no liver disease and patients with cirrhosis). When patients with cirrhosis were compared to those with early HCC (United Network for Organ Sharing modified tumor-node-metastasis stages 1 and 2), the median serum GOLPH2 levels were significantly higher in those with early HCC: 12.69 relative units (range, 1–49) versus 4.39 relative units (range, 0.52–26.78) in patients with cirrhosis (P < 0.0001). Median serum AFP levels were also significantly higher in patients with early HCC than in those with cirrhosis: 11.23 ng/mL (range, 1.48–137,000) versus 6.11 ng/mL (range, 0.28–625) in patients with cirrhosis (P < 0.001). However, when we evaluated the sensitivity and specificity of GOLPH2 in patients with early HCC versus those with cirrhosis, the results showed that GOLPH2 (sensitivity, 62%; specificity, 88%) was significantly better than AFP (sensitivity, 25%; specificity, 97%; P < 0.0001). In summary, our data highlight three points. First, we have shown that GOLPH2 is a better marker than AFP for diagnosing early HCC, partially concurring with the findings from Riener et al.'s study. Second, the sample size is not large enough, so we could not establish the performance of GOLPH2 according to the etiology of the underlying liver disease. Third, before this marker can be applied clinically, multicenter cohorts of validation are still needed. Xiaohua Li Ph.D.*, Kaichun Wu Ph.D.*, Daiming Fan Ph.D.*, * Xijing Hospital of Digestive Diseases, Xi'an, China.

To query the value of GOLPDH2 as a new marker for early diagnosis of hepatocellular carcinoma

Serum golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma.

Assessment of serum GP73, AFP-L3, AFP and AFU detection in the diagnosis of hepatocellular carcinoma

Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma.

Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma.

Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to α fetoprotein.

Diagnostic value of Golgi protein 73 alone and in combination with alpha fetoprotein in hepatocellular carcinoma

Diagnostic Value Of Serum Haptoglobin Protein As Hepatocellular Carcinoma Candidate Marker Complementary To Alpha Fetoprotein

Serological Diagnosis of Hepatocellular Carcinoma: Challenges and Opportunities

Clinical Potential of Serum Prostaglandin A2 As a Novel Diagnostic Biomarker for Hepatocellular Cancer

Diagnostic and Prognostic Value of Serum Golgi Protein 73 in Hepatocellular Carcinoma.

Cancer biomarkers and their clinical application for hepatocellular carcinoma diagnosis

[Clinical Application of Serum Golgi Protein 73 in the Diagnosis and Progress of Hepatocellular Carcinoma].

[Detection and Evaluation of Serum GP73, a Resident Golgi Glycoprotein, As a Marker in Diagnosis of Hepatocellular Carcinoma].

Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma

Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma

Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C

Advances in tumour markers for diagnosis of hepatocellular carcinoma

The Expression of GP73 and AFP in the Tissue of Early HCC and its Significance

Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma

The diagnostic value of golgi protein 73 in patients with hepatocellular carcinoma